METABOLIC MRI IS EMPOWERED BY HYPERPOLARIZATION.
NVISION MAKES IT SIMPLE.
Hyperpolarization enables rapid, precise measurement of natural metabolites. NVision provides fast, robust and easy-to-use hyperpolarization technology for preclinical and clinical research and clinical applications.
POLARIS OFFERS:
High throughput (3min per dose)
Convenient, room temperature processing
Small footprint, no infrastructure adjustment
Simple, robust workflow
Preclinical POLARIS delivery from 2024
Clinical POLARIS following in 2025
POLARIS IS
BASED ON PHIP.
NVision is enabling room-temperature hyperpolarization in 3 minutes based on parahydrogen-induced polarization (PHIP) by combining deep expertise in spin quantum physics, chemistry and engineering.
The power source of PHIP is parahydrogen, a quantum state of hydrogen (singlet state), produced off-site and provided by NVision.
STEP 1
MANIPULATE SPIN-STATE CENTRALLY
.jpg)
Polarization is transferred to a natural metabolite by catalytically adding parahydrogen to a precursor.
STEP 3
TRANSFER POLARIZATION
Parahydrogen is stored in aluminum bottles and shipped to the users. NVision's technology ensures that parahydrogen stays stable for months.
STEP 2
SHIP TO USERS
.jpg)
After purification, the hyperpolarized metabolite, e.g. pyruvate, is ready for injection.
STEP 4
PURIFY AND RELEASE
POLARIS FOR PRECLINICAL USE
NVISION PROVIDES AN END-TO-END SOLUTION, ENABLING FAST RAMP-UP
IN YOUR LAB.
POLARIZER
CONSUMABLES
Active ingredients
Ready to use 13C-pyruvate precursor and catalyst
Parahydrogen cylinders
SUPPORT
Service
Maintenance
Training
Consulting
Research Collaboration
DOSE PRODUCTION IN THREE SIMPLE STEPS
TECHNICAL SPECIFICATIONS
13C-Pyruvate
Lactate, Fumarate, α-Ketoglutarate can be activated via free software upgrade
Probe
>15% at the time of injection
Polarization
3 options available: (a) 0.8 mL at 80 mM, (b) 1 mL at 160mM, (c) 2 mL at 80 mM
Produced Dose
3 minutes for dose production, 10 minutes dose-to-dose interval (incl. cleaning)
Process Time
Integrated fluidic control, no manual manipulation required, semi-automated cleaning after each dose
Fluidic Control
13C-pyruvate precursor, Rh-catalyst,
Parahydrogen gas in multi-dose standard cylinder
Consumables
supplied by NVision
Standard reagents (NVision supports purchasing)
N in a standard cylinder or wall outlet
2
Other Consumables
H 195 cm / W 90 cm / D 85 cm, Weight 350 kg // Footprint < 1 m
2
Dimensions
Fits in standard elevators, can be wheeled between MRI labs
Transportability
Standard power supply, installation outside of 5 G line
Installation
Certification
Fulfills relevant US / EU certifications for laboratory equipment
* subject to change
NVISION'S POLARIZATION PLATFORM PROVIDES EXCELLENT DATA IN UNPRECEDENTED THROUGHPUT AND ROBUSTNESS.
COMPARISON OF PHIP / d-DNP SPECTROSCOPY
MATBIII model (Rat)
Integrated signal intensities over time from dynamic spectroscopy of a slice containing only the tumor of a subcutaneous MATBIII model (Rat).
EL4 lymphoma model (Mouse)
Integrated signal intensities over time from dynamic spectroscopy of a slice containing only the tumor of a subcutaneous EL4 lymphoma model (Mouse).
Wolfgang Gottwald, Department of Nuclear Medicine, Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany.
COMPARISON OF PHIP / d-DNP IMAGING
Luca Nagel, Department of Nuclear Medicine, Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany
NEW APPLICATIONS ARE NOW ENABLED BY FAST DOSE PRODUCTION (4 INJECTIONS WITHIN 1 HOUR).
Wolfgang Gottwald, Department of Nuclear Medicine, Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany.
MATBIII breast cancer model (Rat)
Dynamic spectroscopy of tumor slice after four injections of PHIP pyruvate.
Pyruvate peaks normalized to 1.
FOR MORE INFORMATION
CONNECT WITH US.
FEATURES IN LEADING JOURNALS
AND PRESS RELEASES
